JP2025137626A5 - - Google Patents

Info

Publication number
JP2025137626A5
JP2025137626A5 JP2025117357A JP2025117357A JP2025137626A5 JP 2025137626 A5 JP2025137626 A5 JP 2025137626A5 JP 2025117357 A JP2025117357 A JP 2025117357A JP 2025117357 A JP2025117357 A JP 2025117357A JP 2025137626 A5 JP2025137626 A5 JP 2025137626A5
Authority
JP
Japan
Prior art keywords
chimera
mdm2
amino acid
composition
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025117357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025137626A (ja
Filing date
Publication date
Priority claimed from JP2020532803A external-priority patent/JP2021506814A/ja
Application filed filed Critical
Publication of JP2025137626A publication Critical patent/JP2025137626A/ja
Publication of JP2025137626A5 publication Critical patent/JP2025137626A5/ja
Pending legal-status Critical Current

Links

JP2025117357A 2017-12-15 2025-07-11 安定化ペプチドによって介在される標的タンパク質の分解 Pending JP2025137626A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762599608P 2017-12-15 2017-12-15
US62/599,608 2017-12-15
JP2020532803A JP2021506814A (ja) 2017-12-15 2018-12-14 安定化ペプチドによって介在される標的タンパク質の分解
JP2023096835A JP2023107892A (ja) 2017-12-15 2023-06-13 安定化ペプチドによって介在される標的タンパク質の分解

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023096835A Division JP2023107892A (ja) 2017-12-15 2023-06-13 安定化ペプチドによって介在される標的タンパク質の分解

Publications (2)

Publication Number Publication Date
JP2025137626A JP2025137626A (ja) 2025-09-19
JP2025137626A5 true JP2025137626A5 (https=) 2026-03-10

Family

ID=65201672

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020532803A Pending JP2021506814A (ja) 2017-12-15 2018-12-14 安定化ペプチドによって介在される標的タンパク質の分解
JP2023096835A Pending JP2023107892A (ja) 2017-12-15 2023-06-13 安定化ペプチドによって介在される標的タンパク質の分解
JP2025117357A Pending JP2025137626A (ja) 2017-12-15 2025-07-11 安定化ペプチドによって介在される標的タンパク質の分解

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020532803A Pending JP2021506814A (ja) 2017-12-15 2018-12-14 安定化ペプチドによって介在される標的タンパク質の分解
JP2023096835A Pending JP2023107892A (ja) 2017-12-15 2023-06-13 安定化ペプチドによって介在される標的タンパク質の分解

Country Status (7)

Country Link
US (2) US20200354413A1 (https=)
EP (1) EP3724216A1 (https=)
JP (3) JP2021506814A (https=)
CN (2) CN120118207A (https=)
AU (3) AU2018385697B2 (https=)
CA (1) CA3078682A1 (https=)
WO (1) WO2019118893A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
CN111393519B (zh) * 2019-11-21 2022-11-08 中国药科大学 作为krasg12c/sos1抑制剂的新型订书肽及其用途
WO2021141662A1 (en) * 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
AU2021262752A1 (en) * 2020-04-27 2022-10-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and HDMX-selective p53 peptides and uses thereof
US20220025341A1 (en) * 2020-05-29 2022-01-27 Massachusetts Institute Of Technology Minimal peptide fusions for targeted intracellular protein degradation
IL299163A (en) 2020-06-23 2023-02-01 Genentech Inc Macrocyclic compounds and methods of using them
WO2022047734A1 (zh) * 2020-09-04 2022-03-10 孔二艳 将gfap氨基酸位点作为神经退行性疾病治疗靶标的应用
CN116801908A (zh) 2020-10-14 2023-09-22 丹娜法伯癌症研究院 用于降解病毒和宿主蛋白的嵌合缀合物和使用方法
GB202018608D0 (en) * 2020-11-26 2021-01-13 Zentraza Ltd Adhesive peptides
WO2022129621A1 (en) * 2020-12-18 2022-06-23 John Innes Centre Methods for targeted protein degradation
US20240197694A1 (en) * 2021-03-16 2024-06-20 Cullgen (Shanghai), Inc. Modified proteins and protein binders
CN113845598B (zh) * 2021-09-18 2023-06-30 中国人民解放军海军军医大学 一种蛋白质靶向嵌合体降解mdm2/mdmx蛋白的订书肽缀合物及其用途
US20230257725A1 (en) * 2021-10-22 2023-08-17 Massachusetts Institute Of Technology Minimal Peptide Fusions for Targeted Intracellular Degradation of FOXP3
WO2023150788A2 (en) * 2022-02-07 2023-08-10 Ubiquitx Beta-catenin protein degradation
WO2023203127A1 (en) 2022-04-20 2023-10-26 Vib Vzw Alphabody-based degrader molecules
WO2023225625A2 (en) * 2022-05-19 2023-11-23 The Scripps Research Institute Bifunctional degraders comprising electrophilic protacs that engage dcaf1 and pharmaceutical compositions comprising the same
EP4705323A1 (en) * 2023-05-05 2026-03-11 Senti Biosciences, Inc. Modified degron polypeptides and uses thereof
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物
CN117904060B (zh) * 2023-12-21 2024-09-24 上海大学 一种基于parkin的靶向蛋白泛素化降解剂及其制备方法和应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
EP0958305B1 (en) 1996-07-05 2008-06-04 Cancer Research Technology Limited Inhibitions of the interaction between p53 and mdm2
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
PT1053019E (pt) 1998-01-07 2004-04-30 Debio Rech Pharma Sa Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2649941T3 (es) 2007-02-23 2018-01-16 Aileron Therapeutics, Inc. Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
WO2009137532A1 (en) 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
CA2737922A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2010263056B2 (en) 2009-06-18 2016-01-07 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
US9227995B2 (en) 2010-04-23 2016-01-05 Øyvind Jacobsen Peptides
WO2011156524A2 (en) 2010-06-08 2011-12-15 Laura Sheard Methods and compositions for targeted protein degradation
CN103153335A (zh) 2010-06-30 2013-06-12 布兰代斯大学 小分子靶定的蛋白质降解
EP2590997B1 (en) 2010-07-09 2018-04-04 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2817568A1 (en) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
CA2823837A1 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
US8762795B2 (en) 2010-12-17 2014-06-24 Microsoft Corporation Alerting recipients to errors occurring when accessing external services
US9517252B2 (en) 2011-09-09 2016-12-13 Agency For Science, Technology And Research p53 activating peptides
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9346868B2 (en) 2011-11-14 2016-05-24 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in oncology
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US9464125B2 (en) 2012-02-03 2016-10-11 The Trustees Of Princeton University Engineered potent cytotoxic stapled BH3 peptides
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
WO2013173755A1 (en) 2012-05-18 2013-11-21 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
WO2014052647A2 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053881A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
KR101616603B1 (ko) 2012-10-11 2016-04-28 서울대학교산학협력단 메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
US9783490B2 (en) 2012-12-18 2017-10-10 The Secretary Of State For Health Antimicrobial compounds, their synthesis and applications thereof
WO2014110420A1 (en) 2013-01-10 2014-07-17 Noliva Therapeutics Llc Peptidomimetic compounds
US9115184B2 (en) 2013-03-01 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Light-inducible system for regulating protein stability
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10682388B2 (en) 2014-01-15 2020-06-16 The Board Of Regents Of The University Of Texas System Targeting of PELP1 in cancer therapy
US10040780B2 (en) 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
CA2949535C (en) 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
CA2970683A1 (en) 2014-12-18 2016-06-23 Integrated Dna Technologies, Inc. Crispr-based compositions and methods of use
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9650617B2 (en) 2015-01-28 2017-05-16 Pioneer Hi-Bred International. Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3317294B1 (en) 2015-07-02 2023-03-15 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
US10772962B2 (en) * 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20190002506A1 (en) * 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
CA2995479A1 (en) * 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
CA3014442A1 (en) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
US20190076504A1 (en) 2016-03-23 2019-03-14 Dana-Farber Cancer Institute, Inc. COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
CN118436801A (zh) * 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2025137626A5 (https=)
JP2023506454A5 (https=)
JP2022046569A5 (https=)
TWI250988B (en) Thrombopoietic compounds
CN104211800B (zh) 组织损伤修复中的基质细胞衍生因子1的蛋白酶抗性突变体
JP5761831B2 (ja) 癌及び慢性感染の治療のための作動薬活性を有するil−2由来のポリペプチド
JP2021502810A5 (https=)
TWI886164B (zh) 1價ccap生成物之製造方法
JP2023504914A5 (https=)
JP2019137675A5 (https=)
JP2006514607A5 (https=)
JP2023052258A5 (https=)
ES2855169T3 (es) Conjugados de polipéptido-anticuerpo derivados de aprotinina
JP2020505034A5 (https=)
JP2021073174A5 (https=)
JP2024509241A5 (https=)
WO1983000810A1 (fr) Agent carcinostatique selectif
JP2026032056A5 (https=)
JP2008521426A5 (https=)
JP2023040169A5 (https=)
JP2008500373A5 (https=)
JP2024513559A5 (https=)
TW202140513A (zh) 人類運鐵蛋白受體結合肽
JP2024508969A5 (https=)
JP2008515889A5 (https=)